النرويج - النرويجية - Statens legemiddelverk

orifarm as - insulin glargin - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 e/ ml

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glykogen storage sykdom type ii - andre alimentary tract and metabolism products, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - andre alimentary tract and metabolism products, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunsuppressive - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immune sera og immunglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.